MaxCyte signs platform license agreement with Adicet Bio
MaxCyte’s Flow Electroporation technology and ExPERT platform to support the development of Adicet’s gamma delta T cell therapy gene edited programs
MaxCyte’s Flow Electroporation technology and ExPERT platform to support the development of Adicet’s gamma delta T cell therapy gene edited programs
Understaffing in the lab threatens the collaboration doctors depend on
Researchers receive funding to explore how fluorescent materials can detect the presence of pesticides and herbicides in food production
AliveDx has received IVDR-CE Mark for its multiplexed MosaiQ AiPlex Vasculitis (VAS) assay, designed to speed diagnosis of ANCA-associated vasculitides and Anti-GBM (Goodpasture’s) disease
Direct, high-resolution imaging of cells on membrane inserts without removal or disruption
Dr. Michael Kiebish of BPGbio shares insight into its AI-powered NAi Interrogative Biology Platform and discusses the growing importance of multiomic data
Enhance sample traceability, streamline inventory, and support compliance with a trusted, user-friendly LIMS solution
46 companies and organizations were honored for supporting the association through advertising, sponsorships, and exhibits
Join experts as they discuss the significant hurdles in spatial proteomics and how innovative tools such as the EVOS S1000 Spatial Imaging System are set to redefine research capabilities in this rapidly evolving field
First-of-its-kind study at ADLM 2025 lays the foundation for addressing public health threat
From concept to clinic, NExT gives researchers and developers access to Fujirebio’s unmatched expertise in neurological biomarker testing
Crown Bioscience’s in vitro model offers a physiologically relevant tool to evaluate drug efficacy for hematological diseases
The comprehensive preclinical screening platform was validated using HER2 x TROP2 bsADC as a proof of concept
New findings at ADLM 2025 could remedy this failure
Dr. Stanley F. Lo, DABCC, FADLM, has been elected to serve on the ADLM board of directors as president-elect starting in August 2025